Wilhad Hans Reuter
About Wilhad Hans Reuter
Wilhad Hans Reuter is the Lead Engineer for Upstream Process Development at Alkermes in Waltham, Massachusetts, with a background in bioengineering and chemical engineering from Tufts University.
Company
Wilhad Hans Reuter is currently employed at Alkermes in Waltham, Massachusetts, United States. He holds the position of Lead Engineer in Upstream Process Development. Alkermes is involved in developing innovative medicines in the fields of neuroscience and oncology.
Title
Wilhad Hans Reuter holds the title of Lead Engineer, Upstream Process Development at Alkermes as of January 2022. In this role, he is responsible for overseeing the development and scaling up of upstream bioprocesses for the production of novel biologics.
Work Experience
Before joining Alkermes, Wilhad Hans Reuter built a robust professional background in biotechnology. He worked at LogicBio Therapeutics from 2019 to 2022, progressing from Upstream Engineer I to Upstream Engineer II, specializing in process development. Additionally, he was a Research Associate at the Broad Institute of MIT and Harvard from 2018 to 2019. Earlier in his career, Reuter gained valuable experience as a Chemical Engineering Intern at Genocea in 2018 and as a Research and Development Intern at New England Biolabs from 2016 to 2017.
Education and Expertise
Wilhad Hans Reuter received a Master of Science (MS) in Bioengineering with a concentration in Cell and Bioprocess Engineering from Tufts University, completing his graduate studies in 2021. Prior to this, he earned a Bachelor of Science (BS) in Chemical Engineering from the same university in 2018. His academic background provided a strong foundation for his career in upstream bioprocess development, focusing on the production of novel biologics and biotechnological processes.
Background
Wilhad Hans Reuter has a clear passion for biotechnology, particularly in the arena of creating new therapies to improve patient outcomes. His professional journey reflects his dedication to overcoming challenges in upstream process development, demonstrating practical experience in scaling up bioprocesses for novel biologics and contributing to significant advancements in the field.